Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.
We examined the analgesic effect of nasal salmon calcitonin in patients with acute pain due to recent, nontraumatic osteoporotic vertebral crush fractures. 32 men and 68 postmenopausal women were studied using a prospective, double-blind, placebo-controlled clinical design. Men and women taking 200 IU of nasal salmon calcitonin daily for a period of 28 days had a dramatic decrease of spinal pain. This analgesic effect was accompanied by early mobilization and gradual restoration of the locomotor functions, such as sitting, standing and walking. Patients receiving the placebo nasal spray remained in bed for almost the entire period of observation. The consumption of high doses of paracetamol did not help placebo patients to get out of bed during the 4 weeks of hospitalization. Nasal salmon calcitonin and early mobilization also reduced hydroxyproline excretion, thus preventing massive bone loss during the period of bedrest.
Lyritis
G P
GP
Laboratory for the Research of Musculoskeletal System, University of Athens, KAT Hospital, Greece.
Paspati
I
I
Karachalios
T
T
Ioakimidis
D
D
Skarantavos
G
G
Lyritis
P G
PG
D000281:Administration, Intranasal; D000368:Aged; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D059408:Pain Management; D017698:Postmenopause; D016103:Spinal Fractures / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D002116:Calcitonin